Knight Therapeutics Inc.
KHTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.1% | 11.8% | 20.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 47% | 46.5% | 47% | 47.4% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 17.3% | 12.5% | 8.6% | 17.5% |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 1.2% | -5.1% | -10.2% | 6.4% |
| EPS Diluted | 0.043 | -0.16 | -0.26 | 0.13 |
| % Growth | 126.8% | 38.5% | -300% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | -$0 |